SBC Financials SBC Medical Group Holdings Inc

3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Aug 16, 2026, 10:12 UTC Overview →

Growth & profitability

Revenue has declined 5.3% per year over the past 2 years.
Net income has grown faster than revenue (13.8% vs -5.3% per year).
Operating margin has expanded, at 38.9% in the latest year.
Free cash flow has declined 25.7% per year over the past 2 years.

Financial health

The company holds more cash ($164M) than total debt ($43M).
Total debt has grown faster than revenue (549.0% vs -5.3% per year).
Operating income covered interest expense 455× in the latest year, down from 1560× 2 years ago.
Total debt is 0.6× EBITDA.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$174M	$51M	73.3%	38.9%	20.5%	13.4%	$23M	$43M	$164M
2024	$205M	$47M	76.0%	34.2%	23.9%	17.5%	$18M	$7M	$125M
2023	$194M	$39M	70.9%	36.5%	27.7%	15.2%	$42M	—	$103M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$49M	$11M	73.1%	38.5%	4.1%	2.6%	$22M	$38M	$184M
Mar '26	$43M	$11M	70.5%	41.2%	4.4%	2.9%	$9M	$40M	$167M
Dec '25	$40M	$14M	73.1%	32.5%	5.7%	3.7%	$51M	$43M	$164M
Sep '25	$43M	$13M	70.6%	36.6%	5.2%	4.0%	-$21M	$21M	$127M
Jun '25	$43M	$2M	69.2%	33.6%	1.0%	0.8%	-$9M	$7M	$153M
Mar '25	$47M	$22M	79.7%	51.1%	9.5%	7.6%	$2M	$7M	$132M
Dec '24	$44M	$7M	76.3%	10.6%	3.4%	2.5%	-$8M	$7M	$125M
Sep '24	$53M	$3M	81.5%	26.1%	1.4%	1.0%	$5M	$823153	$137M
Jun '24	$53M	$18M	74.2%	51.4%	209.3%	94.7%	$18M	—	—
Mar '24	$55M	$19M	72.1%	44.6%	208.0%	95.0%	$3M	—	—
Dec '23	$62M	$14M	69.6%	38.5%	10.1%	5.5%	$22M	—	$103M
Sep '23	$47M	$8M	70.9%	42.4%	-150.0%	39.0%	—	—	—
Jun '23	—	$196786	—	—	-3.8%	0.9%	—	—	—
Mar '23	—	$613333	—	—	-16.4%	0.5%	—	—	—
Dec '22	—	$565852	—	—	-16.8%	0.5%	—	—	$485564
Sep '22	—	-$11419	—	—	0.4%	-0.0%	—	—	$579970
Jun '22	—	-$1620	—	—	-6.9%	-0.4%	—	—	$179429

Valuation over time

How the market has priced SBC against its own fundamentals since 2024-09 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 20.5× (Sep '24) to 10.7× (Nov '26).
The price-to-sales ratio has fallen from 4.2× (Sep '24) to 3.1× (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Frequently asked questions

Is SBC growing its revenue and profit?

Over the past 2 years, SBC Medical Group Holdings Inc's revenue has declined 5.3% per year, and net income grown 13.8% per year. These are computed facts, not advice.

How much debt does SBC have?

As of FY2025, SBC Medical Group Holdings Inc reported $43M of total debt against $164M of cash; operating income covered interest expense 455×.

What is SBC's profit margin?

In FY2025, gross margin was 73.3%, operating margin 38.9%, and net margin 29.4%.

What is SBC's P/E ratio?

SBC Medical Group Holdings Inc's P/E (TTM) is 11.14 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the SBC stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 10.7× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.